Carregant...
Phase II Trial of Temsirolimus in Patients with Relapsed or Refractory Multiple Myeloma
In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25 mg IV weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3–4 toxicity included fati...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3771631/ https://ncbi.nlm.nih.gov/pubmed/19261329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2009.01.039 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|